Ing. Daniel Buša
Research specialist, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Office: bldg. C03/125
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 5437 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 11
2023
-
Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft.
Year: 2023, type: Conference abstract
-
AML engraftment in humanized ossicles is not governed by biomaterial selection.
Year: 2023, type: Conference abstract
-
Biomaterial selection does not affect AML engraftment in humanized ossicles.
Year: 2023, type: Conference abstract
-
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing.
Year: 2023, type: Conference abstract
-
Inhibition of acute myeloid leukemia using palbociclib and ponatinib in a patient-derived xenograft model.
Year: 2023, type: Conference abstract
2022
-
. Drug repurposing for venetoclax-resistant acute myeloid leukemia.
Year: 2022, type: Conference abstract
-
Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML
Year: 2022, type: Conference abstract
-
Prediction of novel treatment options for CLL and AML cells based on drug repurposing.
Year: 2022, type: Conference abstract
-
Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.
Year: 2022, type: Conference abstract
2021
-
Acute myeloid leukemia regression induced by palbociclib and ponatinib in patient –derived xenograft model.
Year: 2021, type: Conference abstract